Pasithea Therapeutics Corp. · NASDAQ:KTTA
Pasithea Therapeutics — IPO Roadshow (August 2021)
17 slides from Pasithea Therapeutics's IPO roadshow presentation, Aug 27, 2021
Slide 1: Corporate Presentation
COPYRIGHT © 2021 PASITHEA Corporate Presentation 1
Slide 2: Forward-Looking Statements
COPYRIGHT © 2021 PASITHEA FORWARD - LOOKING STATEMENTS This presentation shall not constitute an offer to sell or the solicitation of an offer to buy securities, nor shall there be an y sale of securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior
Slide 3: Offering Summary
COPYRIGHT © 2021 PASITHEA OFFERING SUMMARY Issuer: Proposed Exchange / Tickers: Offering Type: Securities Issued: Gross Offering Proceeds (including Over- Allotment): Over-Allotment: Estimated Offering Price Range: Pre-Money FD Shares Outstanding: Anticipated Use of Proceeds: Sole Book-Running Manag
Slide 4: Introduction to Pasithea Therapeutics
COPYRIGHT © 2021 PASITHEA INTRODUCTION TO PASITHEA THERAPEUTICS 4 Pasithea Therapeutics is a biotech company at the forefront of neuroscience research Drug development: Focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders Clinic partnership
Slide 5: Investment Highlights
COPYRIGHT © 2021 PASITHEA INVESTMENT HIGHLIGHTS 5 Large Addressable Market With Few Options for Adequate Help Today Capital - Light Infrastructure Diversified Revenue Stream with Significant Revenue and EBITDA Growth Potential Seasoned Leadership Team with Expertise in Neuroscience & Psychopharmacol
Slide 6: Large and Growing Addressable Market
COPYRIGHT © 2021 PASITHEA LARGE AND GROWING ADDRESSABLE MARKET 6 64.6 Million Estimated number of adults suffering from some type of mental health issue in the U.S. 1 US$16.1 Trillion Lost between 2010 and 2030 due to mental health conditions 2 US$19.2 Billion Estimated size of anxiety and depressio
Slide 7: The Stark Reality of the Global Treatment Gap
COPYRIGHT © 2021 PASITHEA THE STARK REALITY OF THE GLOBAL TREATMENT GAP 7 Overall Dropout Only a minority of participants with MDD received minimally adequate treatment HIGH - INCOME LOW - INCOME 1 in 5 people 3 1 in 27 people 3 COUNTRIES TREATMENT RECEIVED OVERALL DROP OUT RATE: 31.7% 4 » Estimates
Slide 8: Even Those Who Do Get Treatment Face Challenges
COPYRIGHT © 2021 PASITHEA EVEN THOSE WHO DO GET TREATMENT FACE CHALLENGES 8 Current treatments for psychiatric disorders are inadequate. Conventional medicines have low success rates in long - term treatment, and New types of drugs are limited by working through the same mechanisms . DIZZINESS HEADA
Slide 9: Primary Focus: Developing New Molecular Entities and/or Novel Biologic Drugs
COPYRIGHT © 2021 PASITHEA PRIMARY FOCUS: DEVELOPING NEW MOLECULAR ENTITIES AND/OR NOVEL BIOLOGIC DRUGS 9 Drugs targeting novel mechanism of action Next 24 MONTHS Phase 1 Phase 2 Phase 3 Develop 3 lead compounds focused on psychiatric and neurological disorders Focuses on: • Targets that can be devel
Slide 10: Secondary Focus: Clinic Partnerships to Deliver Ketamine Treatments
COPYRIGHT © 2021 PASITHEA SECONDARY FOCUS: CLINIC PARTNERSHIPS TO DELIVER KETAMINE TREATMENTS 10 Will provide intravenous infusions of ketamine to treat mental health disorders, such as Treatment - Resistant Depression (TRD) and Post - Traumatic Stress Disorder (PTSD) Will give immediate access to p
Slide 11: Clinic Partnerships to Deliver Ketamine Treatments – United Kingdom
COPYRIGHT © 2021 PASITHEA SECONDARY FOCUS: CLINIC PARTNERSHIPS TO DELIVER KETAMINE TREATMENTS – UNITED KINGDOM 11 Operations in the UK will involve providing business support services to registered healthcare providers who will assess pati ent s and administer IV infusion of ketamine, if appropriate
Slide 12: UK Clinic Partnership
COPYRIGHT © 2021 PASITHEA UK CLINIC PARTNERSHIP 12 • Capital - light partnership with Zen Healthcare • Zen Healthcare has two locations in London: Knightsbridge and Baker Street • Provides immediate exposure in the UK • Existing management structure and qualified GPs, pharmacists, therapists and psy
Slide 13: Clinic Partnerships to Deliver Ketamine Treatments – United States
COPYRIGHT © 2021 PASITHEA SECONDARY FOCUS: CLINIC PARTNERSHIPS TO DELIVER KETAMINE TREATMENTS –UNITED STATES Operations in the US will involve providing business support services to registered healthcare providers who will assess patients and administer IV infusion of ketamine, if appropriate. Pasit
Slide 14: US Partnership
COPYRIGHT © 2021 PASITHEA US PARTNERSHIP 14 NYC Base Deal Terms: • Plan to market and roll out nationwide 22.5K Pasithea pays IV Doc a fixed monthly fee of $22,500 The IV Doc 50,000 Patients 7 Years of operating • Partnered with The IV Doc, a leading provider of administrative and support services t
Slide 15: Pasithea's Competitive Landscape in the Mental Health Sector
COPYRIGHT © 2021 PASITHEA PASITHEA’S COMPETITIVE LANDSCAPE IN THE MENTAL HEALTH SECTOR 15
Slide 16: Improving Mental Health Treatments and Driving Shareholder Value
COPYRIGHT © 2021 PASITHEA IMPROVING MENTAL HEALTH TREATMENTS AND DRIVING SHAREHOLDER VALUE 16 Seasoned Leadership Team with Expertise in Neuroscience & Psychopharmacology Diversified Revenue Stream with Significant Revenue and EBITDA Growth Potential Capital - Light Infrastructure Large Addressable
Slide 17: Contact
COPYRIGHT © 2021 PASITHEA 17 www.pasitheaclinics.com Contact: Ed Tsuker Head of Capital Markets EF Hutton etsuker@efhuttongroup.com